TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB [clinicaltrials:NCT00023400]

Bio2RDF uri

TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB [clinicaltrials:NCT00023400]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00023400

Bio2RDF identifier

NCT00023400

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00023400

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00023400

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Primary Objective: ...... harmacokinetic studies.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

TBTC Study 23B:Intensive PK of ...... action in Patients With HIV-TB

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Impact of nelfinavir (given at 1250mg bid as part of a combination antiretroviral regimen) on area under the curve for rifabutin and 25-O-desacetyl rifabutin when rifabutin is given 300 mg bi-weekly as part of tuberculosis chemotherapy. [clinicaltrials_resource:f4e1ab4f2f1e9a2f08449948eecec2f7]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

collaborator [clinicaltrials_vocabulary:collaborator]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

completion date [clinicaltrials_vocabulary:completion-date]

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00023400 [clinicaltrials_resource:372307fa84c0eff5d98de901f09ba835]

enrollment [clinicaltrials_vocabulary:enrollment]

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2001-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

Rifabutin [clinicaltrials_resource:79a4745cac85ba5674a29f920822f23a]

Nelfinavir [clinicaltrials_resource:a75add373fe7ba59114f096b9a21954f]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Rifabutin [clinicaltrials_resource:0873c60740b3276b384569eae4aec237]

Nelfinavir [clinicaltrials_resource:1465f6bcc84621c4157f80921afa4762]

keyword [clinicaltrials_vocabulary:keyword]

http://www.w3.org/2001/XMLSchema#string

tuberculosis

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

link [clinicaltrials_vocabulary:link]

Click here for more information about the Tuberculosis Trials Consortium (TBTC) [clinicaltrials_resource:933cff17ea172c799256c7e5eaef4f6d]

location [clinicaltrials_vocabulary:location]

Central Arkansas Veterans Health System [clinicaltrials_resource:2f65639d5c452009e9e6b9ae4a532f06]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00023400

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

TBTC Study 23B:Intensive Pharm ...... With a Rifabutin-Based Regimen

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CDC-NCHSTP-2587

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Debra Benator, MD [clinicaltrials_resource:5a3f1f5ef50aa55be58fa46a2aaa5d1e]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

secondary id [clinicaltrials_vocabulary:secondary-id]

23B

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

start date [clinicaltrials_vocabulary:start-date]

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00023400 study design [clinicaltrials_resource:e89abab51b759514c6c48796cb3f5b11]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00023400

verification date [clinicaltrials_vocabulary:verification-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00023400

http://www.w3.org/2001/XMLSchema#string

title

TBTC Study 23B:Intensive PK of ...... action in Patients With HIV-TB

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

TBTC Study 23B:Intensive PK of ...... B [clinicaltrials:NCT00023400]

@en